search
Back to results

Effects of X-STOP® Versus Laminectomy Study (EXELS)

Primary Purpose

Lumbar Spinal Stenosis

Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
X-STOP®
Laminectomy
Sponsored by
Medtronic Spine LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lumbar Spinal Stenosis focused on measuring Lumbar Spinal Stenosis, X-STOP® IPD, Interspinous process decompression, Neurogenic Intermittent Claudication

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age > 50
  2. Has completed at least 6 months of conservative therapy which may include but is not limited to epidural steroid injection, oral steroids, NSAIDS, analgesics, physical therapy, and/or spinal manipulation.
  3. Symptoms of leg/buttock/groin pain with or without back pain that are exacerbated by lumbar extension and relieved in flexion. If back pain is also present it must be partially relieved when the patient flexes.
  4. Diagnosis of NIC due to lumbar stenosis at 1 or 2 lumbar levels confirmed by X-ray, MRI or CT.
  5. Subject is a surgical candidate with disease severity justifying that BOTH laminectomy and X-STOP IPD placement are clinically appropriate treatment options.
  6. Baseline score of >2.0 in the Physical Function domain of the Zurich Claudication Questionnaire (ZCQ). Because this is a post-market study, the Inclusion Criteria are consistent with FDA approved X-STOP indication for use (moderately impaired physical function), which requires a ZCQ physical function score of >2.0.
  7. Subject is able to walk at least 50 feet.
  8. Subject is willing and able to comply with required follow-up testing and expected to be physically able to return for evaluation at scheduled follow-up visits.
  9. Subject is able to understand the risks and benefits of participating in the study.
  10. Subject understands and has signed the study informed consent form.

Exclusion Criteria:

  1. Spinal stenosis involving more than 2 lumbar levels.
  2. Any previous lumbar spine surgery.
  3. Subject has unremitting pain in any spinal position or axial back pain only without leg/buttock/groin pain.
  4. Evidence that subject's symptoms are due to vascular claudication.
  5. Subject has significant instability of the lumbar spine, e.g., isthmic spondylolisthesis or degenerative spondylolisthesis greater than Grade 1 (on a scale of 1 to 4).
  6. Subject has an ankylosed segment at the affected level(s).
  7. Subject has significant scoliosis (Cobb angle is greater than 25 degrees).
  8. Subject has cauda equina syndrome defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction.
  9. Subject has a fixed motor deficit or known peripheral neuropathy.
  10. Subject has a degenerative neurologic disease.
  11. Subject has any mass lesions (e.g. disc herniations, synovial cysts, spinal tumors).
  12. Any evidence of spinal or systemic infection.
  13. Subject has a history of spinous process fracture or pars interarticularis fracture.
  14. Subject has history or radiographic evidence of 1 or more osteoporotic fractures (e.g., vertebral, hip, wrist) OR subject has severe osteoporosis of the spine or hip, defined as bone mineral density (BMD) in the spine or hip more than 2.5 SD below the mean of adult normals. If the Investigator suspects osteoporosis, a DEXA scan should be done.
  15. Subject has a known allergy to the implant materials (this includes titanium or titanium alloy and polyetheretherketone for X-STOP IPD).
  16. Subject has a bleeding disorder or an active systemic disease such as HIV, hepatitis, etc.
  17. Subject has any medical condition that would limit availability for follow-up.
  18. Subject has a recent history of narcotic abuse (i.e., within last 3 years).
  19. Subject is immunologically suppressed, or has received or is receiving 7.5 milligrams prednisone (or equivalent) daily for more than six months immediately prior to enrollment.
  20. Subject is currently involved in a study of another investigational product that may affect the outcome of this study.
  21. Subject is not able to undergo MRI or tolerate closed MRI scanning. Subject is pregnant or of child-bearing potential and not currently on adequate birth control method.
  22. Subject is pregnant or of child-bearing potential and not currently on adequate birth control method.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Investigational

    Control

    Arm Description

    X-STOP® PEEK IPD

    Laminectomy

    Outcomes

    Primary Outcome Measures

    Change from baseline in the Zurich Claudication Questionnaire (ZCQ)

    Secondary Outcome Measures

    ZCQ symptom severity, physical function and satisfaction; pain rating; quality of life (SF-36®); operative data; canal, subarticular and neuroforaminal measurements on MRI; spinal stability using flexion/extension (serious adverse events)

    Full Information

    First Posted
    November 12, 2007
    Last Updated
    December 6, 2017
    Sponsor
    Medtronic Spine LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00558129
    Brief Title
    Effects of X-STOP® Versus Laminectomy Study
    Acronym
    EXELS
    Official Title
    Prospective Randomized Trial Comparing X-STOP® Interspinous Process Decompression® System Versus Laminectomy for Treatment of Neurogenic Intermittent Claudication
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2012
    Overall Recruitment Status
    Withdrawn
    Study Start Date
    November 2007 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    November 2011 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Medtronic Spine LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    To determine if the effectiveness of the X-STOP® implant is equivalent (non-inferior) to that of conventional laminectomy in patients with lumbar spinal stenosis as measured by the Zurich Claudication Questionnaire.
    Detailed Description
    The clinical study described herein aims to compare surgical outcomes of X-STOP® Interspinous Process Decompression® (IPD) system implantation and conventional laminectomy in subjects requiring surgical intervention due to symptoms of lumbar spinal stenosis (LSS) and a confirmed diagnosis on MRI, X-ray or CT. Patients with LSS meeting entry criteria will be randomized to either X-STOP® IPD or laminectomy treatment. Patients will remain blinded to the procedure received. The primary study outcome is group differences in the Zurich Claudication Questionnaire (ZCQ) at 12 months post-operative. In addition, each subject will undergo follow-up assessment at 2 weeks and 2, 12 and 24 months post-operative. The secondary objective is to compare safety profiles and the radiographic outcomes between groups using pre- and post-operative MRI and flexion/extension X-rays, to measure changes in canal and neuroforaminal cross sectional areas and spinal stability, respectively.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lumbar Spinal Stenosis
    Keywords
    Lumbar Spinal Stenosis, X-STOP® IPD, Interspinous process decompression, Neurogenic Intermittent Claudication

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Investigational
    Arm Type
    Experimental
    Arm Description
    X-STOP® PEEK IPD
    Arm Title
    Control
    Arm Type
    Active Comparator
    Arm Description
    Laminectomy
    Intervention Type
    Device
    Intervention Name(s)
    X-STOP®
    Other Intervention Name(s)
    X-STOP® PEEK IPD
    Intervention Description
    Surgical implantation of X-STOP IPD device
    Intervention Type
    Procedure
    Intervention Name(s)
    Laminectomy
    Intervention Description
    Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
    Primary Outcome Measure Information:
    Title
    Change from baseline in the Zurich Claudication Questionnaire (ZCQ)
    Time Frame
    1 year post-operative
    Secondary Outcome Measure Information:
    Title
    ZCQ symptom severity, physical function and satisfaction; pain rating; quality of life (SF-36®); operative data; canal, subarticular and neuroforaminal measurements on MRI; spinal stability using flexion/extension (serious adverse events)
    Time Frame
    Out to 2 years postoperative

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age > 50 Has completed at least 6 months of conservative therapy which may include but is not limited to epidural steroid injection, oral steroids, NSAIDS, analgesics, physical therapy, and/or spinal manipulation. Symptoms of leg/buttock/groin pain with or without back pain that are exacerbated by lumbar extension and relieved in flexion. If back pain is also present it must be partially relieved when the patient flexes. Diagnosis of NIC due to lumbar stenosis at 1 or 2 lumbar levels confirmed by X-ray, MRI or CT. Subject is a surgical candidate with disease severity justifying that BOTH laminectomy and X-STOP IPD placement are clinically appropriate treatment options. Baseline score of >2.0 in the Physical Function domain of the Zurich Claudication Questionnaire (ZCQ). Because this is a post-market study, the Inclusion Criteria are consistent with FDA approved X-STOP indication for use (moderately impaired physical function), which requires a ZCQ physical function score of >2.0. Subject is able to walk at least 50 feet. Subject is willing and able to comply with required follow-up testing and expected to be physically able to return for evaluation at scheduled follow-up visits. Subject is able to understand the risks and benefits of participating in the study. Subject understands and has signed the study informed consent form. Exclusion Criteria: Spinal stenosis involving more than 2 lumbar levels. Any previous lumbar spine surgery. Subject has unremitting pain in any spinal position or axial back pain only without leg/buttock/groin pain. Evidence that subject's symptoms are due to vascular claudication. Subject has significant instability of the lumbar spine, e.g., isthmic spondylolisthesis or degenerative spondylolisthesis greater than Grade 1 (on a scale of 1 to 4). Subject has an ankylosed segment at the affected level(s). Subject has significant scoliosis (Cobb angle is greater than 25 degrees). Subject has cauda equina syndrome defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction. Subject has a fixed motor deficit or known peripheral neuropathy. Subject has a degenerative neurologic disease. Subject has any mass lesions (e.g. disc herniations, synovial cysts, spinal tumors). Any evidence of spinal or systemic infection. Subject has a history of spinous process fracture or pars interarticularis fracture. Subject has history or radiographic evidence of 1 or more osteoporotic fractures (e.g., vertebral, hip, wrist) OR subject has severe osteoporosis of the spine or hip, defined as bone mineral density (BMD) in the spine or hip more than 2.5 SD below the mean of adult normals. If the Investigator suspects osteoporosis, a DEXA scan should be done. Subject has a known allergy to the implant materials (this includes titanium or titanium alloy and polyetheretherketone for X-STOP IPD). Subject has a bleeding disorder or an active systemic disease such as HIV, hepatitis, etc. Subject has any medical condition that would limit availability for follow-up. Subject has a recent history of narcotic abuse (i.e., within last 3 years). Subject is immunologically suppressed, or has received or is receiving 7.5 milligrams prednisone (or equivalent) daily for more than six months immediately prior to enrollment. Subject is currently involved in a study of another investigational product that may affect the outcome of this study. Subject is not able to undergo MRI or tolerate closed MRI scanning. Subject is pregnant or of child-bearing potential and not currently on adequate birth control method. Subject is pregnant or of child-bearing potential and not currently on adequate birth control method.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Volker Sonntag, MD
    Organizational Affiliation
    Barrow Neurological Institute, St. Joseph's Hospital and Medical Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Effects of X-STOP® Versus Laminectomy Study

    We'll reach out to this number within 24 hrs